NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ:CLDA), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, today reported strong quarterly revenue growth in all of its businesses. Total revenues from continuing operations for the third quarter ended December 31, 2007 rose 31% to $10.5 million from $8.0 million for the three months ended December 31, 2006 on strong sales growth in both the PGxHealth and Cogenics business units.
